Amgen Inc. Dossier
Qualitative Analysis
Business overview
Amgen Inc. is one of the world's largest independent biotechnology companies, specializing in the discovery, development, manufacture, and marketing of human therapeutics based on advanced cellular and molecular biology. The company's diversified portfolio spans six core therapeutic areas: cardiovascular disease, oncology, inflammation, rare disease, bone health, and respiratory medicine. Amgen's principal products include blockbuster therapies such as Prolia, Repatha, Otezla, Enbrel, Evenity, Xgeva, Tepezza, Blincyto, Nplate, and Tezspire. The company operates globally, with its largest concentration of sales and marketing forces in the United States and Europe, alongside expanding operations in the Asia-Pacific region, Latin America, and the Middle East.
Research as of 5 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Amgen is developing long-acting MariTide across chronic weight management, Type 2 diabetes, cardiovascular outcomes, heart failure, obstructive sleep apnea, treatment switching, weight-loss maintenance and elevated liver fat.
Expected impact: The program is intended to create a differentiated obesity and cardiometabolic franchise based on monthly, every-eight-week or quarterly dosing in selected studies.
Amgen is expanding domestic biologics manufacturing and building a science-and-innovation center with advanced automation and digital capabilities.
Expected impact: The investments are intended to expand production capacity, strengthen supply-chain resilience and accelerate next-generation therapeutic discovery.
Amgen is expanding its oncology portfolio through IMDELLTRA/IMDYLLTRA development across small-cell lung-cancer settings, Phase 3 xaluritamig studies in prostate cancer, and the acquired Dark Blue targeted-protein-degradation program in acute myeloid leukemia.
Expected impact: The initiative could broaden Amgen's oncology revenue base across lung cancer, prostate cancer and early-stage leukemia research.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
The acquisition added first-in-class small-molecule targeted protein degraders, including an investigational MLLT1/3-targeting program intended for acute myeloid leukemia, complementing Amgen's oncology and targeted-protein-degradation research.
Strategic Partnerships
The collaboration supports lifecycle expansion of TEZSPIRE into eosinophilic esophagitis and COPD while advancing inhaled TSLP-targeting sunakiment in asthma.
Terms: For TEZSPIRE, Amgen and AstraZeneca share global costs, profits and losses equally after AstraZeneca pays Amgen a mid-single-digit royalty.
BeOne is responsible for commercializing IMDELLTRA in China following regulatory approval, extending Amgen's reach in an important oncology market.
The collaboration underpins Amgen's STEAP1-targeted BiTE program, including Phase 3 development in metastatic castration-resistant prostate cancer.